CRISPR Therapeutics AG CRSP shares are trading higher Monday after the company announced preclinical data for its investigational programs for the treatment of cardiovascular disease.
What Happened: CRISPR is set to announce preclinical data at the American Heart Association (AHA) Scientific Sessions 2023 on Nov. 11. The data will be presented in two sessions.
One of the presentations covers CTX310, which has been found to reduce ANGPTL3 protein and triglyceride levels in non-human primates after a single dose. The other is on CTX320, which the company said reduces lipoprotein(a) levels in non-human primates after a single dose.
"We're excited to share these preclinical data at AHA highlighting the progress made across our in vivo programs targeting ANGPTL3 and Lp(a). The findings demonstrate the potential of a one-time treatment to produce clinically meaningful, long-lasting reductions in risk factors for atherosclerotic cardiovascular disease," said Phuong Khanh Morrow, chief medical officer of CRISPR Therapeutics.
Read Next: Top 5 Health Care Stocks That May Fall Off A Cliff This Month
CRSP Price Action: CRISPR shares were up 7.08% at $54.60 at the time of publication, according to Benzinga Pro.
Photo: Chokniti Khongchum from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
